Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Head For EMA's Orphan Drugs Committee

Executive Summary

A key priority for the new chair will involve reinforcing how the European Medicines Agency’s orphan drugs committee interacts and communicates with other scientific committees at the agency and other international partners.

Related Content

Orphan Drugs Study Compares EMA's Significant Benefit With HTA's Relative Effectiveness Assessments
New Guidance Brings Welcome Clarity on Practical Application of EU Orphan Drugs Law





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts